PFBT
TVRD

Parkside Financial Bank & Trust’s Tvardi Therapeutics TVRD Stock Holding History

Parkside Financial Bank & Trust’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$333 – 2116
2022
Q4 		$333 Hold
1
– – ﹤0.01% 1935
2022
Q3 		$0 Hold
1
– – ﹤0.01% 1980
2022
Q2 		$0 Sell
1
-4
-80% -$1.4K ﹤0.01% 1981
2022
Q1 		$2K Buy
+5
New +$2.05K ﹤0.01% 1666
2021
Q4 		– Sell
-8
Closed -$4K – 1937
2021
Q3 		$4K Buy
8
+2
+33% +$1K ﹤0.01% 1382
2021
Q2 		$3K Buy
+6
New +$3.8K ﹤0.01% 1481

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkside Financial Bank & Trust's TVRD Position: Q1 2023 in Review

Parkside Financial Bank & Trust sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 1 share — an estimated $333 sold.

Parkside Financial Bank & Trust first reported a position in TVRD in Q2 2021 and held it in 6 quarters. The position peaked at $4K in Q3 2021. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Parkside Financial Bank & Trust reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 1 Tvardi Therapeutics share in Q1 2023, an estimated $333.
  • Parkside Financial Bank & Trust first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 6 quarters.
  • Parkside Financial Bank & Trust's Tvardi Therapeutics position peaked at $4K in Q3 2021.
  • 163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2023, filed 4 May 2023.